NCT04831281View on ClinicalTrials.gov

ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial)

PHASE2TerminatedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

January 20, 2022

Primary Completion Date

April 19, 2023

Study Completion Date

April 19, 2023

Conditions
Parkinson Disease DementiaDementia With Lewy Bodies
Interventions
DRUG

ATH-1017

Daily subcutaneous injection of ATH-1017 in a pre-filled syringe

DRUG

Placebo

Daily subcutaneous injection of Placebo in a pre-filled syringe

Trial Locations (10)

19462

Keystone Clinical Studies LLC, Plymouth Meeting

30030

iResearch Atlanta, LLC, Decatur

33407

Premiere Research Institute, West Palm Beach

33486

Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton

48334

QUEST Research Institute, Farmington Hills

97210

Summit Research Network, Portland

97225

Center for Cognitive Health, Portland

98007

Northwest Clinical Research Center, Bellevue

98034

Evergreen Health Research, Kirkland

99202

Inland Northwest Research LLC, Spokane

Sponsors

Lead Sponsor

Athira Pharma
All Listed Sponsors
lead

Athira Pharma

INDUSTRY

NCT04831281 - ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial) | Biotech Hunter | Biotech Hunter